Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$76.13 USD

76.13
2,260,926

+2.01 (2.71%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zacks.com featured highlights: Incyte, AMC Entertainment, Mercadolibre, PTC and Clean Harbors

Zacks.com featured highlights: Incyte, AMC Entertainment, Mercadolibre, PTC and Clean Harbors

    Dispose of These 5 Toxic Stocks or Sell Short for Gains

    Toxic stocks are susceptible to outside shocks and are loaded with huge debt.

      Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi

      Incyte (INCY) announced new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi.

        Arpita Dutt headshot

        5 Top-Ranked Drug Stocks that are Broker Favorites

        With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.

          Incyte (INCY) Initiates Essential Thrombocythemia Trial

          Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.

            AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View

            AstraZeneca's (AZN) Q3 results were mixed. It expects 2017 core earnings to be toward the favorable end of the guidance range of a decline in low-to-mid teen percentage.

              Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal

              Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.

                What's in the Offing for Intercept (ICPT) in Q3 Earnings?

                Intercept Pharmaceuticals, Inc. (ICPT) is likely to see a dip in Ocaliva sales when it reports third-quarter results on Nov 1.

                  Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite

                  Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite

                    What's in the Offing for Exelixis (EXEL) in Q3 Earnings?

                    Exelixis, Inc. (EXEL) received a major boost with the FDA's approval of Cabometyx tablets and we expect investor focus on the drug's uptake when it reports third-quarter results.

                      Will Radius Health (RDUS) Disappoint This Earnings Season?

                      Radius Health (RDUS) has a disappointing track record and we expect the trend to continue when it reports third-quarter results on Nov 2.

                        Get Rid of These 5 Toxic Stocks or Sell Short for Profit

                        Toxic stocks are vulnerable to outside shocks and are burdened with high amounts of debts. Also, the price of toxic stocks is inflated.

                          Why Incyte (INCY) Might Surprise This Earnings Season

                          Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                            Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                            Alexion's (ALXN) blockbuster drug, Soliris, continues to perform well and the company is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell.

                              Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco

                              Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.

                                Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?

                                Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                                  5 Toxic Stocks to Abandon or Sell Short for Gains

                                  Toxic stocks are susceptible to external shocks and are loaded with high amounts of debts. Also, the price of toxic stocks is irrationally high.

                                    Agenus (AGEN) Remains Focused on Drug Development Programs

                                    Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.

                                      J&J's Arthritis Candidate Sirukumab Denied FDA Approval

                                      J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.

                                        Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite

                                        Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite

                                          5 Toxic Stocks to Discard or Sell Short for Profit

                                          Toxic stocks are exposed to outside shocks and are burdened with high levels of debts. Also, the price of toxic stocks is artificially inflated.

                                            Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

                                            Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

                                              Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda

                                              Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.

                                                Mark Vickery headshot

                                                Top Research Reports for Bank of America, Pepsi & American Express

                                                Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), American Express (AXP), and Pepsi (PEP).

                                                  Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected

                                                  Lilly (LLY) and Incyte announced that they will re-submit the new drug application (NDA) for their rheumatoid arthritis (RA) drug, baricitinib much faster than previously expected.